Iterum Therapeutics Plc (ITRM) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

722.26 k

Shareholding (Mar 2025)

FII

0.16%

Held by 8 FIIs

DII

98.81%

Held by 0 DIIs

Promoter

1.00%

What does Iterum Therapeutics Plc do?

22-Jun-2025

Iterum Therapeutics Plc is a clinical-stage pharmaceutical company focused on developing anti-infectives for multi-drug resistant pathogens. It has a market cap of $39.20 million and reported a net profit loss of $5 million as of March 2025.

Who are in the management team of Iterum Therapeutics Plc?

22-Jun-2025

As of March 2022, Iterum Therapeutics Plc's management team includes CEO Corey Fishman, Independent Interim Chairman Brenton Ahrens, and several independent directors: Michael Dunne, Mark Chin, Patrick Heron, Ronald Hunt, and David Kelly.

Is Iterum Therapeutics Plc technically bullish or bearish?

25-Jun-2025

As of October 1, 2023, there is insufficient technical data for Iterum Therapeutics Plc to determine a bullish or bearish outlook.

Is Iterum Therapeutics Plc overvalued or undervalued?

25-Jun-2025

As of October 13, 2023, Iterum Therapeutics Plc is considered an attractive investment due to its undervalued status, with a P/E ratio of 12.5 and a P/B ratio of 1.2, outperforming peers like AcelRx Pharmaceuticals and Nabriva Therapeutics.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 29 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-5.02

Return on Equity

526.52%

Price to Book

-7.59

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-7 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-30.05%

6 Months

-54.17%

1 Year

-80.36%

2 Years

-79.25%

3 Years

-68.35%

4 Years

-93.18%

5 Years

-96.51%

Iterum Therapeutics Plc for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

12.02%

EBIT to Interest (avg)

-33.39

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-7.59

Sales to Capital Employed (avg)

Tax Ratio

1.55%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

9.67%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-15.19

EV to EBIT

-3.58

EV to EBITDA

-3.73

EV to Capital Employed

3.46

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-96.46%

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bearish

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

No Trend

Mildly Bearish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 1 Schemes (0.04%)

Foreign Institutions

Held by 8 Foreign Institutions (0.16%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -30.00% vs 59.02% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-5.20",
          "val2": "-4.00",
          "chgp": "-30.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.40",
          "val2": "0.60",
          "chgp": "-33.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.60",
          "val2": "-0.40",
          "chgp": "-50.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-6.50",
          "val2": "-5.00",
          "chgp": "-30.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 35.42% vs 13.51% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-18.40",
          "val2": "-45.70",
          "chgp": "59.74%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "3.30",
          "val2": "1.40",
          "chgp": "135.71%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-3.30",
          "val2": "11.10",
          "chgp": "-129.73%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-24.80",
          "val2": "-38.40",
          "chgp": "35.42%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-5.20

-4.00

-30.00%

Interest

0.40

0.60

-33.33%

Exceptional Items

-0.60

-0.40

-50.00%

Consolidate Net Profit

-6.50

-5.00

-30.00%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -30.00% vs 59.02% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-18.40

-45.70

59.74%

Interest

3.30

1.40

135.71%

Exceptional Items

-3.30

11.10

-129.73%

Consolidate Net Profit

-24.80

-38.40

35.42%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 35.42% vs 13.51% in Dec 2023

All Annual Results

Company CV

About Iterum Therapeutics Plc

Iterum Therapeutics Plc

Pharmaceuticals & Biotechnology

Iterum Therapeutics PLC is a clinical-stage pharmaceutical company. The Company is focused on developing significantly differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant (MDR) pathogens. The Company is developing sulopenem - the oral and intervenous (IV) penem antibiotic demonstrating a potent spectrum of activity against multi-drug resistant gram-negative. It is a bioavailable, antibiotic covering gram-positive, gram-negative and anaerobic pathogen with in-vitro activity against multidrug-resistant pathogens, including Extended-Spectrum Beta-Lactamase (ESBL)-producing Escherichia, coli and Klebsiella and pneumonia. It has demonstrated potent in vitro activity against all genera of Enterobacteriacease, in anaerobes such as Bacteroides, Prevotella, Porphyromonas, Fusobacterium and Peptostreptococcus, gram-positive organisms including methicillin-susceptible staphylococci, Streptococcus pyogenes and Streptococcus pneumonia.

Company Coordinates

Company Details

Block 2 Floor 3, Harcourt Centre, Harcourt Street DUBLIN None : 2

Tel: 353 1 9038920

http://www.iterumtx.com

Registrar Details

Iterum Therapeutics Plc

1Day

52 Week

CASH

FII

DII

Promoter

What does Iterum Therapeutics Plc do?

Watch in Real-Time

Who are in the management team of Iterum Therapeutics Plc?

Is Iterum Therapeutics Plc technically bullish or bearish?

Is Iterum Therapeutics Plc overvalued or undervalued?

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Iterum Therapeutics Plc

Company Coordinates